| Characteristic |
Statistic/
Category |
Treatment- Naïve
(n=155) |
Treatment -
Experienced
(n=102) |
p |
| Gender |
n
Female
Male |
155
123 (79.4%)
32 (20.7%) |
102
85 (83.3%)
17 (16.7%) |
.52a |
| Race |
n
Minority
Non-minority |
154
26 (16.9%)b
128 (83.1%) |
102
21 (20.6%)c
81 (79.4%) |
.51a |
| BMI |
n
M ± SD
Range |
155
27.3 ± 6.1
15, 49 |
101
27.5 ± 6.2
12, 44 |
.78d |
| Age (years) |
n
M ± SD
Range |
155
43.2 ± 10.2
19, 64 |
102
44.4 ± 11.1
21, 69 |
.38d |
| Age at diagnosis (years) |
n
M ± SD
Range |
155
40.7 ± 10.1
19, 61 |
102
37.8 ± 10.1
18, 61 |
.03d |
| Duration of MS (years) |
n
M ± SD
Range |
155
2.5 ± 5.4
0, 26 |
102
6.6† ± 6.0
0, 29 |
<.001d |
| Last recorded EDSS |
n
Mdn
Range |
40
1.5
0, 6 |
23
3.0
1, 7 |
<.001e |
| Readiness Survey |
n
Mdn
Range |
153
2.0
1, 4 |
102
3.0
1, 5 |
<.001e |
| Decisional Balance
Pro score
Con score
Combined |
n
M ± SD
Range |
154
21.8 ± 3.7
8, 25 |
102
21.9 ± 3.5
9, 25 |
.78d |
n
M ± SD
Range |
154
9.4 ± 4.1
5, 25 |
102
8.4 ± 3.3
5, 19 |
.04d |
n
M ± SD
Range |
154
12.4 ± 6.0
-6, 20 |
102
13.5 ± 4.8
-3, 20 |
.11d |
| MS Self-Efficacy
Function subscale |
n
M ± SD
Range |
154
795.5 ± 141.2
100, 900 |
102
711.1 ± 157.0
290, 900 |
<.001d |
|
Control subscale |
n
M ± SD
Range |
154
650.3 ± 192.3
90, 900 |
102
554.7 ± 194.3
110, 900 |
<.001d |
|
Combined |
n
M ± SD
Range |
154
1445.7 ± 315.0
210, 1800 |
102
1265.8 ±306.0
550, 1800 |
<.001d |
| Self-Injection Competence |
n
M ± SD
Range |
146
7.9 ± 2.1
1, 10 |
88
8.0 ± 1.9
3, 10 |
.59d |
|
| Table 2: Baseline Characteristics: Treatment-Naïve vs. Treatment-
Experienced Patients M = Mean; SD = Standard Deviation; Mdn =
Median; aBased on chi-square and Fisher’s Exact Test. bIncludes 15
African-American, 9 Hispanic, 1 Native American, and 1 “Other”
patient. cIncludes 16 African-American, 2 Hispanic, 2 Native
American, and 1 Asian patient. dBased on independent t test. eBased
on Mann-Whitney U test |
